Renaissance Technologies
ABOS icon

Renaissance Technologies’s Acumen Pharmaceuticals ABOS Stock Holding History

Renaissance Technologies’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.12M Buy
473,946
+50,846
+12% +$130K ﹤0.01% 2214
2025
Q4 		$893K Sell
423,100
-161,192
-28% -$320K ﹤0.01% 2345
2025
Q3 		$999K Buy
584,292
+337,704
+137% +$467K ﹤0.01% 2479
2025
Q2 		$286K Sell
246,588
-10,112
-4% -$10.9K ﹤0.01% 3060
2025
Q1 		$282K Sell
256,700
-513
-0.2% -$733 ﹤0.01% 2943
2024
Q4 		$442K Sell
257,213
-48,887
-16% -$118K ﹤0.01% 2899
2024
Q3 		$759K Sell
306,100
-32,000
-9% -$86.8K ﹤0.01% 2597
2024
Q2 		$818K Buy
+338,100
New +$1.08M ﹤0.01% 2437
2023
Q4 		– Sell
-87,400
Closed -$363K – 3686
2023
Q3 		$363K Buy
87,400
+42,600
+95% +$263K ﹤0.01% 2852
2023
Q2 		$215K Buy
44,800
+7,355
+20% +$35.2K ﹤0.01% 3273
2023
Q1 		$152K Buy
37,445
+5,145
+16% +$26.9K ﹤0.01% 3368
2022
Q4 		$174K Buy
+32,300
New +$217K ﹤0.01% 3469
2022
Q1 		– Sell
-21,609
Closed -$146K – 4035
2021
Q4 		$146K Buy
+21,609
New +$238K ﹤0.01% 3612

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Renaissance Technologies's ABOS Position: Q1 2026 in Review

Renaissance Technologies increased its Acumen Pharmaceuticals (ABOS) stake by 12% in Q1 2026, buying an estimated $130K and bringing the position to 473,946 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2214.

Renaissance Technologies first reported a position in ABOS in Q4 2021 and has held it in 13 quarters since. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Renaissance Technologies held 473,946 shares of Acumen Pharmaceuticals worth $1.12M as of Q1 2026.
  • Renaissance Technologies bought 50,846 Acumen Pharmaceuticals shares in Q1 2026, an estimated $130K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2214 holding.
  • Renaissance Technologies first reported a position in Acumen Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.